Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730226 | 0.84 | HTR6 (0.77) | HTR6HTR2CADRA2A | |
| SCHEMBL730225 | 0.84 | HTR6 (0.77) | HTR6HTR2CADRA2A | |
| SCHEMBL13442963 | 0.84 | HTR6 (0.77) | HTR6HTR2CADRA2A | |
| SCHEMBL13442973 | 0.82 | HTR6 (0.76) | HTR6HTR2CCCKBR | |
| Hydrochloric Acid SCHEMBL3613570 | 0.81 | HTR6 (0.77) | HTR6HTR2CCCKBR | |
| Hydrochloric Acid SCHEMBL3613572 | 0.81 | HTR6 (0.77) | HTR6HTR2CCCKBR | |
| Hydrochloric Acid SCHEMBL3613619 | 0.79 | HTR6 (0.77) | HTR6HTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL3615615 | 0.79 | HTR6 (0.77) | HTR6HTR2CADRA2A | |
| SCHEMBL730737 | 0.75 | HTR6 (0.53) | HTR6HTR2CCCKBRACLY | |
| SCHEMBL730736 | 0.75 | HTR6 (0.53) | HTR6HTR2CCCKBRACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138210-B2 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-03-20 | — | — | US | disclosed |
| US-8138210-B2 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-03-20 | — | — | US | disclosed |
| US-20080027073-A1 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-31 | — | — | US | disclosed |
| US-20080027073-A1 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027073-A1 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, GPR6 | HTR6 1/4885HTR2C 14/4885CCKBR 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.